Tetanus toxoid-derived peptide–MHC class II-specific CD4+ T-cell receptor (TT-specific TCR) (TT-specific TCR)

The Tetanus toxoid-derived peptide–MHC class II-specific CD4+ T-cell receptor is a specialized immune receptor that recognizes processed fragments of the tetanus toxin presented by Major Histocompatibility Complex (MHC) class II molecules (PubMed: 2561436). Because most individuals have been vaccinated against tetanus, they possess a robust pool of memory CD4+ T cells expressing these receptors, which can be rapidly reactivated upon exposure to the antigen (PubMed: 1554973). In a therapeutic context, these TCRs are being leveraged in adoptive cell therapies, such as TCR-engineered T cells, to provide "helper" signals that enhance the persistence and activity of anti-tumor CD8+ T cells (PubMed: 30249029). By engineering T cells to express TT-specific TCRs, researchers aim to exploit pre-existing immune memory to boost responses against cancer or chronic infections (PubMed: 33106617). These receptors typically target well-characterized epitopes such as the P2 (830–844) or P30 (947–967) peptides of the tetanus toxin (PubMed: 2463344). The interaction between the TCR and the peptide-MHC complex is highly specific and depends on the patient's HLA profile, primarily HLA-DR alleles (PubMed: 7511055).

Other names

Tetanus toxoid-specific T-cell receptorTT-peptide-MHC II-specific TCRCD4+ TCR specific for tetanus toxoidTetanus toxoid-reactive TCRTT-specific CD4+ TCR

The receptor binds to specific tetanus toxoid peptides (e.g., P2 or P30) presented by MHC class II molecules on the surface of antigen-presenting cells. This binding event triggers a signaling cascade through the CD3 complex, leading to the activation of the CD4+ T cell, secretion of pro-inflammatory cytokines like IL-2 and IFN-gamma, and the provision of "help" to B cells and CD8+ T cells (PubMed: 30249029, PubMed: 2561436).